REPLIMUNE GROUP INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
REPLIMUNE GROUP INC. - More news...
REPLIMUNE GROUP INC. - More news...
- Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
- Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1
- Replimune to Provide Data Update on June 3, 2020
- Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors
- Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
- Replimune to Present at Two Upcoming Investor Conferences
- Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones
- Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization
- Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference
- Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer
- Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference
- Replimune Announces Pricing of Public Offering
- Replimune Announces Proposed Public Offering
- Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update
- Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)
- Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients
- Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
- Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Replimune to Present at Chardan’s 3rd Annual Genetic Medicines Conference
- Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update
- Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference
- Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update
- Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab
- Replimune to Present at Upcoming Investor Conferences
- Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019
- Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update
- Replimune to Present at Two Upcoming Investor Conferences
- Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference
